Springer Nature
Browse
13046_2021_2153_MOESM1_ESM.docx (4.96 MB)

Additional file 1 of Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug

Download (4.96 MB)
journal contribution
posted on 2021-12-03, 04:43 authored by Emilia Alors-Perez, Ricardo Blázquez-Encinas, Sonia Alcalá, Cristina Viyuela-García, Sergio Pedraza-Arevalo, Vicente Herrero-Aguayo, Juan M. Jiménez-Vacas, Andrea Mafficini, Marina E. Sánchez-Frías, María T. Cano, Fernando Abollo-Jiménez, Juan A. Marín-Sanz, Pablo Cabezas-Sainz, Rita T. Lawlor, Claudio Luchini, Laura Sánchez, Juan M. Sánchez-Hidalgo, Sebastián Ventura, Laura Martin-Hijano, Manuel D. Gahete, Aldo Scarpa, Álvaro Arjona-Sánchez, Alejandro Ibáñez-Costa, Bruno Sainz, Raúl M. Luque, Justo P. Castaño
Additional file 1.

Funding

Ministerio de Economía y Competitividad Ministerio de Ciencia, Innovación y Universidades Instituto de Salud Carlos III Fundación Científica Asociación Española Contra el Cáncer Boehringer Ingelheim Fonds GETNE Fondazione Italiana per la Ricerca sul Cancro Ministero della Salute Fondazione Cariverona: Oncology Biobank Project “Antonio Schiavi”

History

Usage metrics

    Journal of Experimental & Clinical Cancer Research

    Categories

    Keywords

    Pancreatic cancerSplicing-spliceosomeSF3B1Pladienolide-Bcancer stem cells

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC